决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Conference report: Advanced Therapies Week 2023.
2023年先进疗法周会议在美国佛罗里达州迈阿密举行。
2023年先进疗法周会议在美国佛罗里达州迈阿密举行。在为期4天、内容丰富的演讲、专题讨论、公司展示和社交活动中,一个明确的信息浮现出来:细胞疗法的未来已经到来。来自产业界和学术界的演讲者和专题讨论嘉宾所涵盖的及时议题包括异体和自体细胞疗法、细胞制造自动化、用于自身免疫性疾病的细胞和基因疗法、基因递送技术、肿瘤学中的CAR-T 细胞疗法、封闭式细胞疗法制造,以及如何服务于小患者群体。尽管仍存在一些挑战,但这十年很可能将见证美国FDA批准许多细胞和基因疗法,以及用于其制造的新设备。
The Advanced Therapies Week 2023 conference took place in Miami, FL, USA. Over the course of 4 days packed with talks, panels, company showcases and networking events, a clear message emerged: the future of cell therapy is here. Timely topics covered by speakers and panelists from industry and academia included allogeneic and autologous cell therapies, cell manufacture automation, cell and gene therapy for autoimmune diseases, gene delivery technology, chimeric antigen receptor T-cell therapy in oncology, closed cell therapy manufacturing and how to serve small patient populations. While some challenges remain, this decade will likely witness the US FDA approval of many cell and gene therapies, as well as new devices for their manufacture.
MEMBER ACCOUNT
登录成功会直接打开下一页。